Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
European Commission Approves Roche’s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) […]
European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional […]
FDA Approves Roche’s Evrysdi for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
New Pivotal Data Demonstrate Clinical Benefit of Roche’s Glofitamab, a Potential First-in-class Bispecific Antibody for People With Aggressive Lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new pivotal data on its investigational […]
Roche’s Polivy Combination Approved by European Commission for People With Previously Untreated Diffuse Large B-cell Lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted […]
CHMP Recommends EU Approval of Roche’s Tecentriq as Adjuvant Treatment for a Subset of People with Early-stage Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee […]
U.S. FDA Grants Priority Review to Roche’s Actemra/Roactemra for the Treatment of COVID-19 in Hospitalised Adults
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration […]
Ad Hoc Announcement Pursuant to Art. 53 Lr Roche Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-stage Small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III SKYSCRAPER-02 study, evaluating the […]
New Data for Roche’s Evrysdi (risdiplam) Demonstrate Long-term Efficacy and Safety in a Broad Population of People with Spinal Muscular Atrophy (SMA)
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for Evrysdi® (risdiplam) in spinal muscular atrophy […]
New Two-year Data for Roche’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision with Fewer Treatments for People with Two Leading Causes of Vision Loss
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new two-year data from its phase […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more